Leukemia Research
Volume 33, Issue 12 , Pages 1581-1583 , December 2009

How do JAK2-inhibitors work in myelofibrosis: An alternative hypothesis

  • Alessandro M. Vannucchi

      Affiliations

    • Corresponding Author InformationCorrespondence address: Department of Hematology, University of Florence, Viale Morgagni 85, 50134 Florence, Italy. Tel.: +39 055 7947 688; fax: +39 055 7947 688.

Received 3 June 2009 ,Revised 3 June 2009 ,Accepted 3 June 2009.

References 

  1. Mesa R, Gale RP. Hypothesis: how do jak2-inhibitors work in myelofibrosis. Leuk Res. 2009;33:1156–1157
  2. Pardanani A. Jak2 inhibitor therapy in myeloproliferative disorders: rationale, preclinical studies and ongoing clinical trials. Leukemia. 2008;22:23–30
  3. Pardanani A, GotlIb J, Jamieson C, Cortes J, Talpaz M, Stone RM. A phase i study of TG101348, an orally bioavailable JAK-selective inhibitor, in patients with myelofibrosis. Blood. 2008;112:97A
  4. Verdstovsek S, Kantarjian HM, Pardanani AD, Thomas D, Cortes J, Mesa RA. The JAK inhibitor, INCB018424, demonstrates durable and marked clinical responses in primary myelofibrosis and post-polycythemia/essential thrombocythemia myelofibrosis. Blood. 2008;1762A
  5. Vannucchi AM, Migliaccio AR, Paoletti F, Chagraoui H, Wendling F. Pathogenesis of myelofibrosis with myeloid metaplasia: lessons from mouse models of the disease. Semin Oncol. 2005;32:365–372
  6. Lataillade JJ, Pierre-Louis O, Hasselbalch HC, Uzan G, Jasmin C, Martyre MC. Does primary myelofibrosis involve a defective stem cell niche? From concept to evidence. Blood. 2008;112:3026–3035
  7. Jiang L, Li Z, Rui L. Leptin stimulates both JAK2_dependent and JAK2-independent signaling pathways. J Biol Chem. 2008;
  8. Vainchenker W, Dusa A, Constantinescu SN. Jaks in pathology: role of janus kinases in hematopoietic malignancies and immunodeficiencies. Semin Cell Dev Biol. 2008;19:385–393
  9. Rambaldi A, Dellacasa CM, Salmoiraghi S, Spinelli O, Ferrari ML, Gattoni E. A phase 2a study of the histone-deacetylase inhibitor ITF2357 in patients with JAK2V617F positive chronic myeloproliferative neoplasms. Blood. 2008;112:100A
  10. Guerini V, Barbui V, Spinelli O, Salvi A, Dellacasa C, Carobbio A. The histone deacetylase inhibitor ITF 2357 selectively targets cells bearing mutated JAK2(V617F). Leukemia. 2008;22:740–747

PII: S0145-2126(09)00281-1

doi: 10.1016/j.leukres.2009.06.001

Leukemia Research
Volume 33, Issue 12 , Pages 1581-1583 , December 2009

Article Tools

* Image Usage & Resolution